Dr Reddy's Labs gains 2%, relaunches anti-inflammatory drug

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Shares of Dr Reddy's Laboratories climbed more than 2 percent intraday Wednesday on relaunching anti-inflammatory drug in a different colour.

"Dr Reddy's today announced relaunch of its Esomeprazole magnesium delayed-release capsules (20 mg and 40 mg) in the US market," says the pharma major, adding the relaunch is due to a change in capsule colour.

Esomeprazole is a therapeutic equivalent generic version of Nexium that is a registered trademark of AstraZeneca AB Corporation.

On November 10, the US court issued a temporary restraining order (TRO) against Dr Reddy's on selling Nexium generic due to usage of same purple colour for capsule.

The company had launched this drug in September, which has market size of USD 1.8-2 billion. The drug, which is used to treat gastroesophageal reflux disease, is expected to contribute Rs 5-7 earnings per share annually for DRL.

At 12:22 hours IST, the scrip of Dr Reddy's Laboratories was quoting at Rs 3,159, up Rs 56.70, or 1.83 percent on the BSE.Posted by Sunil Shankar Matkar